FFC#11/2015

Genetically diverse mice as innovative model for cystic fibrosis

AREA 3 Bronchopulmonary infection

FFC#11/2015

Genetically diverse mice as innovative model for cystic fibrosis
€ 0 still needed
0%
€ 65.000 goal

pRINCIPAL INVESTIGATOR

Nicola Ivan Lorè (Divisione di Immunologia, Trapianti e Malattie Infettive – Istituto Scientifico San Raffaele, Milano)

Researchers

5

Category

AREA 3 Bronchopulmonary infection

Duration

2 years

Goal

€ 65.000

Funds raised

€ 65.000

Objectives

The progression and severity of pulmonary disease do not appear to correlate with the CFTR gene defect only. The host genetic background variability is known to determine different susceptibility to P. aeruginosa airway infection and related immune responsiveness. The existing CF mouse models do not represent the heterogeneity of the human population and are often lacking of pulmonary phenotype. Recently, a Collaborative Cross (CC) mouse was constructed having more recombination and genetic variation compared with that of other reference panels mouse population. Thus, this project will take advantage of unique CC mouse and existing CF ΔF508-/- mouse model to cross them and generate a new combined mouse model (CC and ΔF508-/-). It is expected to show different susceptibility to airway infection and thus to impact on different CF research areas.

WHO ADOPTED THE PROJECT

Delegazione FFC di Villa d’Almè

€ 15.000

Delegazione FFC di Reggio Calabria con gli amici del primo Trofeo Neurone

€ 8.000

Delegazione FFC di Torino

€ 20.000

Delegazione FFC di Tradate Gallarate

€ 14.000

Delegazione FFC di Bologna

€ 8.000

Delegazione FFC di Torino

€ 20.000

OTHER PROJECTS

Discover the other projects

GMRF#1/2026

Exploring the role of PKD1 in promoting CFTR stability and function at the cell surface

FFC#1/2026

Mapping proteins regulating CFTR mRNA stability to identify new therapeutic targets for nonsense mutations

FFC#2/2026

Evaluating the potential of phosphodiesterase inhibitors to enhance the efficacy of CFTR modulators and support personalized therapeutic approaches